Publications

The immunotherapy approach supported by CIEF is based on peer-reviewed scientific research conducted over several years.

The publications below describe the biological mechanisms of the method and its anti-tumor effects observed in preclinical models.

While laboratory results can be promising, new therapeutic approaches must undergo rigorous clinical testing before their safety and potential effectiveness in patients can be evaluated.

These studies therefore form the scientific foundation for further investigation toward clinical trials.

Peer-Reviewed Scientific Publications

1. Janotová T, Jalovecká M, Auerová M, Švecová I, Bruzlová P, et al. (2014)
   The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model.
   PLoS ONE 9(1): e85222.
   doi:10.1371/journal.pone.0085222
2. Waldmannová E, Caisová V, Fáberová J, Sváčková P, Kovářová M, et al. (2016)
   The use of Zymosan A and bacteria anchored to tumor cells for effective cancer immunotherapy: B16-F10 murine melanoma model.
   International Immunopharmacology 39: 295–306.
3. Caisová V, Vieru A, Kumžáková Z, Glaserová S, Husníková H, et al. (2016)
   Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.
   BMC Cancer 16: 940.
   doi:10.1186/s12885-016-2982-x
4. Caisová V, Uher O, Nedbalová P, Jochmanová I, et al. (2018)
   Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
   International Immunopharmacology 59: 86–96.
5. Caisová V, Li L, Gupta G, Jochmanová I, Jha A, et al. (2019)
   The significant reduction or complete eradication of subcutaneous and metastatic lesions in a pheochromocytoma mouse model after immunotherapy using mannan-BAM, TLR ligands, and anti-CD40.
   Cancers 11, 654.
   doi:10.3390/cancers11050654
6. Uher O, Caisova V, Hansen P, Kopecky J, Chmelar, et al. (2019)
   Coley’s immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.
   Seminars in Oncology.
   doi:10.1053/j.seminoncol.2019.10.004
7. Medina R, Wang H, Caisová V, Cui J, Indig IH, et al. (2020)
   Induction of immune response against metastatic tumors via vaccination of mannan-BAM, TLR ligands, and anti-CD40 antibody (MBTA).
   Advanced Therapeutics.
   doi:10.1002/adtp.202000044
8. Uher O, Caisova V, Padoukova L, Kvardova K, Masakova K, et al. (2021)
   Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.
   Cancer Immunology, Immunotherapy.
   doi:10.1007/s00262-021-02920-9
9. Lookian PP, Zhao D, Medina R, Wang H, Zenka J, et al. (2021)
   Mannan‐BAM, TLR ligands, anti‐CD40 Antibody (MBTA) vaccine Immunotherapy: A review of current evidence and applications in Glioblastoma.
   International Journal of Molecular Sciences 22: 3455.
   doi:10.3390/ijms22073455
10. Uher O, Huynh TT, Zhu B, Horn LA, Caisova V, et al. (2021)
    Identification of immune cell infiltration in murine pheochromocytoma during combined mannan-BAM, TLR ligand, and anti-CD40 antibody-based immunotherapy.
    Cancers 13, 3942.
    doi:10.3390/cancers13163942
11. Frejlachova A, Lencova R, Venhauerova A, Skalickova M, Uher O, et al. (2023)
    The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma.
    International Immunopharmacology 118: 110150.
    doi:10.1016/j.intimp.2023.110150
12. Uher O, Hadrava Vanova K, Lencova R, Frejlachova A, Wang H, et al. (2023)
    Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.
    Frontiers in Endocrinology 14: 1030412.
    doi:10.3389/fendo.2023.1030412
13. Ye J, Wang H, Medina R, Chakraborty S, Sun M, et al. (2023)
    rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses.
    Journal of Experimental Clinical Cancer Research 42: 63.
    doi:10.1186/s13046-023-02744-8
14. Wang H, Medina R, Ye J, Zhang Y, Chakraborty S, et al. (2024)
    rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells.
    Advanced Science 2308280.
    doi:10.1002/advs.202308280
15. Uher O, Vanova KH, Petrlakova K, Labitt R, Lencova R, et al. (2024)
    Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model.
    Best Practice & Research Clinical Endocrinology & Metabolism 101941.
    doi:10.1016/j.beem.2024.101941
16. Uher O, Vanova KH, Labitt R, Petrlakova K, Ye J, et al. (2025)
    Neoadjuvant intratumoral MBTA immunotherapy prevents distant metastases and recurrence in murine models.
    Cancer Letters 612: 217464.
    doi:10.1016/j.canlet.2025.217464
17. Uher O, Vanova KH, Taïeb D, Calsina B, Robledo M, et al. (2024)
    The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.
    Endocrine Reviews 45: 521–552.
    doi:10.1210/endrev/bnae005
18. Ye J, Wang H, Chakraborty S, Sang X, Xue Q, et al. (2025)
    Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy.
    International Journal of Molecular Sciences 26: 1340.
    doi:10.3390/ijms26031340
19. Vanova KH, Uher O, Kraus M, Miklovicova S, Honigova K, et al. (2025)
    Development of succinate dehydrogenase subunit B-deficient tumor models for preclinical immunotherapy testing.
    Cancer Letters 632: 217969.
    doi:10.1016/j.canlet.2025.217969
20. Zhang Y, Ye J, Sun M, Chakraborty S, Valenzuela A, et al. (2025)
    rWTC-MBTA Vaccine, Alone and Enhanced with Anti-PD1, Elicits Immune Responses against CNS and Peripheral B-Cell Lymphoma.
    Advanced Science e11605.
    doi:10.1002/advs.202511605